• The collab aims to educate small-to-medium-sized clinics on how to effectively deliver novel psychedelic treatments, if FDA-approved.
• Osmind has tie-ups with over 1,000 clinics in the U.S. that offer psychedelic treatment.
• The news comes days after Trump’s executive order to fast-track review for psychedelic treatments and boost federal funding for research. 

Shares of Compass Pathways (CMPS) are rising in premarket trading after the company collaborated with Osmind, one of the largest tech platform networks in the U.S. that supports interventional psychiatry practices offering psychedelic treatment to patients with mental health issues. 

The news comes on the heels of President Donald Trump’s executive order to fast-track the FDA review of psychedelic treatments that can be used to cure post-traumatic stress disorder, among other mental health illnesses, and increased federal research funding for such options.

CMPS Extends Rally On Osmind Collaboration 

CMPS stock rose as much as 5% on Tuesday before the opening bell, following a 42% rally on Monday, which was its best day in 2026.

As part of the collaboration, the company will inform Osmind on how to administer its psychedelic treatment, COMP360, which currently has a “Breakthrough Therapy” designation from the FDA. COMP360 is a synthetic psilocybin therapy that is being explored to cure treatment resistant depression.

“Through this collaboration, we will support Osmind and their network to prepare for the potential delivery of psychedelic treatments, learning alongside them to better understand the needs of independent practices,” said  Dr. Steve Levine, Chief Patient Officer at Compass Pathways. “Together, we aim to inform scalable, patient-centered care models that uphold the highest standards of quality as clinics nationwide prepare for the potential future delivery of COMP360.”

CMPS Stock: How Did Retail Traders React?

On Stocktwits, retail sentiment remained ‘extremely bullish’ while messaging volumes more than quadrupled over the last 24 hours.

One user on the platform believes CMPS is the only company that has the data needed to be FDA-approved.

CMPS stock has gained more than 37% so far this year, while the S&P 500 has risen about 4% over the same period.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: USA Rare Earth Strikes $2.8B Deal To Buy Serra Verde’s Operations In Brazil – How Does The US Benefit From It?